{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 26 of 122', '8. For sexually active females of childbearing potential, use of a highly effective method of', 'birth control, defined as one that results in a low failure rate (ie, < 1% per year) when', 'used consistently and correctly, as follows:', 'Combined (estrogen- and progestogen-containing) hormonal contraception associated', 'with inhibition of ovulation (oral, intravaginal, or transdermal)', 'Progestogen-only hormonal contraception associated with inhibition of ovulation', '(oral, injectable, or implantable)', 'Intrauterine device (IUD)', 'Intrauterine normone-releasing system (IUS)', 'Bilateral tubal occlusion', 'Vasectomized partner', 'Sexual abstinence', 'If a highly effective single method of birth control is not used, an effective double-barrier', 'method of contraception should be used (eg, male condom in conjunction with a cervical', 'cap, diaphragm, or contraceptive sponge with spermicide).', 'Where local requirements are more stringent, a highly effective method of birth control', 'must be used.', '4.2 Exclusion Criteria', 'Each subject eligible to participate in this study must not meet any of the following exclusion', 'criteria:', '1. Uncertain clinical diagnosis of peanut allergy.', '2. History of severe or life-threatening anaphylaxis or anaphylactic shock within 60 days', 'before screening.', '3.', 'History of eosinophilic esophagitis (EoE); other eosinophilic GI disease; chronic,', 'recurrent, or severe gastroesophageal reflux disease (GERD); symptoms of dysphagia', '(eg, difficulty swallowing, food \"getting stuck\") or recurrent GI symptoms of any', 'etiology.', '4. History of a mast cell disorder including systemic mastocytosis, urticaria pigmentosa,', 'chronic idiopathic or chronic physical urticaria beyond simple dermatographism (eg, cold', 'urticaria, cholinergic urticaria), and hereditary or idiopathic angioedema.', '5. Severe persistent asthma (criteria step 5 or 6; National Heart, Lung, and Blood Institute', '[NHLBI], 2007) (Table 19).', '6. Mild or moderate asthma (criteria steps 1-4; NHLBI, 2007) that is uncontrolled or', 'difficult to control as defined by any of the following:', 'Forced expiratory volume in the first second of expiration (FEV1) < 80% of predicted,', 'or ratio of FEV1 to forced vital capacity (FEV1/FVC) < 75% of predicted, with or', 'without controller medications (aged > 6 years only and able to do spirometry)', 'Inhaled corticosteroid dosing of > 500 g daily fluticasone (or equivalent based on', 'NHLBI 2007 dosing chart)']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 27 of 122', 'One hospitalization due to asthma within 1 year before screening', 'Emergency department visit due to asthma within 6 months before screening', '7. History of high-dose corticosteroid medication use (eg, > 3 days at 1-2 mg/kg of', 'prednisone or equivalent) as defined by any of the following:', 'Oral steroid administered daily for > 1 month within 1 year before screening', 'Burst steroid course (oral, intravenous [IV], or intramuscular administration) within', '3 months before screening', 'More than 2 burst steroid courses (oral, IV, or intramuscular administration) > 1 week', 'in duration within 1 year before screening', '8. History of chronic disease (except asthma, atopic dermatitis, or allergic rhinitis) that is or', 'is at significant risk of becoming unstable or requiring a change in a chronic therapeutic', 'regimen, including malignancies within 5 years before screening and autoimmune', 'diseases.', '9. History of cardiovascular disease including uncontrolled or inadequately controlled', 'hypertension.', '10. Use of beta-blockers (oral), angiotensin-converting enzyme inhibitors, angiotensin', 'receptor blockers, calcium channel blockers, or tricyclic antidepressants.', '11. Unable to discontinue antihistamines 5 half-lives of the medication before the SPT, first', 'day of dose escalation, and food challenges.', '12. Lack of an available palatable vehicle food to which the subject is not allergic.', '13. Allergy to oat.', '14. Hypersensitivity to epinephrine or any of the excipients in the epinephrine auto-injector.', '15. Use of any therapeutic antibody or any immunomodulatory therapy (including', 'immunosuppressive medications) except aeroallergen or venom immunotherapy used in', 'the maintenance phase within 6 months before screening.', '16. Received at least 1 dose of AR101 in another Aimmune-sponsored study.', '17. Currently receiving or received within 5 years before screening any type of peanut', 'allergen immunotherapy.', '18. Participated in another clinical study within 30 days or 5 half-lives of the investigational', 'product, whichever is longer, before screening.', '19. In the build-up phase of immunotherapy for any nonpeanut allergen (ie, has not reached', 'maintenance dosing).', '20. Resides at the same place as another subject in any interventional trial sponsored by', 'Aimmune or lives in the same household or is a dependent of a sponsor employee or site', 'staff involved in conducting this study.', '21. Pregnant or breastfeeding.', '22. Any other condition (concurrent disease, infection, comorbidity, or psychiatric or', 'psychological disorders) or reason that may interfere with the ability to participate in the', 'study, cause undue risk, or complicate the interpretation of data, in the opinion of the', 'investigator or medical monitor.']\n\n###\n\n", "completion": "END"}